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discoid lupus erythematosusTo inform our ongoing efforts to develop deﬁning features to be incorporated into a novel set of classiﬁca-
tion criteria for discoid lupus erythematosus (DLE), we conducted a literature review using the Ovid
MEDLINE database. A search was performed to identify studies reporting criteria used to distinguish DLE
fromother cutaneous lupus erythematosus subtypes.We examinedwhich clinical, histopathologic, and se-
rologic features have data to support their use as effective features in distinguishing DLE from other poten-
tial diseasemimickers and cutaneous lupus subsets. Through our search, wewere also able to identify gaps
that exist in the literature which can inform future directions for research endeavors. We found that local-
ization of lesions, characteristic features of damage, and the absence of high titer Ro/SSA antibody seem
most effective in differentiating DLE from other cutaneous lupus erythematosus subtypes. Histopathologic
features and class of immunoreactant deposition appear to be less helpful.
Published by Elsevier Inc. on behalf ofWomen's Dermatologic Society. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
The grouping schema for the set of disorders known as cutaneous
lupus erythematosus (CLE) has undergone various iterations
throughout the years. Its complicated history has been described in
detail elsewhere, but there is no agreement on how best to deﬁne
and classify CLE (Sontheimer, 1997). Consensus on the current state
of CLE deﬁnition and classiﬁcation was expressed in 2013 at the 3rd
International Conference on Cutaneous Lupus Erythematosus,
where an international group of lupus experts mutually agreed
upon the need for better deﬁnitions, grouping schema, and classiﬁca-
tion criteria for CLE variants (Merola et al., 2015).
The results of one study demonstrate the uncertainty that exists
over the classiﬁcation of CLE subtypes. 43% of patients with subacutepartment of Veterans Affairs
velopment, Biomedical Lab-
ancouver, BC, June 11, 2015.
rth).
en's Dermatologic Society. Thiscutaneous lupus erythematosus (SCLE) were classiﬁed with discoid
rash, whereas 32% of generalized discoid lupus erythematosus
(DLE) patients were classiﬁed with psoriasiform and/or polycyclic
type lesions (Table 1) (Beutner et al., 1991). Either these patients
have overlap between two CLE subtypes or there is some confusion
over what a discoid rash really is.
Based upon the results of an initial Delphi questionnaire, a deci-
sion was made to begin by developing classiﬁcation criteria for DLE
for use in research endeavors. Since this subtype of chronic CLE is
considered one of the most prevalent and readily recognizable
forms of CLE because of its resultant scarring, chronic CLE was
determined to be a good starting point for the classiﬁcation of the
larger disease state. To inform a consensus on the particular features
that serve to best characterize DLE, it is useful to examine the
literature for the features that have proven effective in differentiating
DLE from other CLE subtypes in prior studies. Although there have
been studies investigating the characteristics that distinguish
DLE from other CLE subtypes, there is still much-needed research to
be done.
This review highlights gaps that exist in the literature to describe
future directions for research that might help physicians to better
classify this disease. It is our hope that classiﬁcation criteria will
provide investigators with a foundation upon which to baseis an open access article under the CC BY-NC-ND license (http://creativecommons.
Table 2
Summary of literature search results
Terms used Number of
relevant results
Relevant articles
Discoid lupus erythematosus and
diagnosis
9 Al-Refu and Goodﬁeld
(2010)
Walling and
Sontheimer (2009)
Kontos et al. (2005)
Fabbri et al. (2003)
Lee et al. (1994)
David-Bajar et al.
(1992)
Jerden et al. (1990)
Bangert et al. (1984)
Nieboer et al. (1987)
Discoid lupus erythematosus and
classiﬁcation
1 Beutner et al. (1993)
Table 3
Potential diagnostic criteria proposed by two sets of authors (Walling and Sontheimer,
2009; Fabbri et al., 2003)
Walling and Sontheimer (2009) Fabbri et al. (2003)
- Indurated coin-shaped plaque
affecting the scalp, face, ears,
anterior neck, extensor arm
- Well-demarcated disk-shaped lesion
associated with follicular plugging
- Lesions most often located on exposed
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guage with which to communicate effectively about this patient
population.
Methods
An extensive literature search using the Ovid MEDLINE database
was conducted from January 1, 1946, to April 14, 2015. Search
terms included “discoid lupus erythematosus”, “diagnosis”, and “clas-
siﬁcation”. Articles in English and pertaining to humans were includ-
ed. A search of “discoid lupus erythematosus” and “classiﬁcation”
returned 39 articles, of which one was relevant. A search of “discoid
lupus erythematosus” and “diagnosis” returned 436 articles, of
which nine were relevant (Table 2). Studies included in the review
were those that reported on the role of clinical, histologic, or serologic
features in the diagnosis or classiﬁcation of patients with DLE.
Historical context
Few authors have proposed criteria for the diagnosis of DLE.
Fabbri et al. (2003) and Walling and Sontheimer (2009) authored
the only two papers to describe characteristics that, if present,
might allow physicians to make a diagnosis of DLE (Table 3). The
criteria were created as diagnostic criteria derived from the authors’
clinical expertise andwere not validated. Neither set of authors com-
ment on the number of criteria thatmust be fulﬁlled in order to reach
a diagnosis of DLE. However, the criteria proposed by these authors
serve as a good framework bywhich to examine the different clinical,
histologic, and serologic features that might go into a classiﬁcation
criteria of DLE and to discuss the literature that supports or disproves
the incorporation of these features. Although these authors proposed
diagnostic criteria, the purpose of the Delphi initiative is to create
classiﬁcation criteria for research purposes. Although we use the di-
agnostic criteria by these two sets of authors as a framework for our
discussion, it is important to recognize that their goals were targeted
and may be useful for a different purpose.
Clinical characteristics of DLE activity
Fabbri et al. (2003) and Walling and Sontheimer (2009) describe
active DLE as being round, affecting sun-exposed areas, and involving
follicular plugging. Walling and Sontheimer (2009) elaborate further
on the appearance of the active lesion as being indurated with pe-
ripheral scale. David-Bajar et al. (1992) performed a study in 1992
to deﬁne features that could help distinguish patients with DLE
from those with SCLE. They examined the features of 27 patients—11
with DLE and seven with SCLE—and found localization of lesions on
the scalp/face was more prevalent in DLE than in SCLE (David-Bajar
et al., 1992). However, a different study found a signiﬁcantly higher
incidence ofmalar rash in SCLE patients than in thosewith both local-
ized and generalized DLE (Beutner et al., 1991) (Table 1). Precipita-
tion by sun exposure was less helpful in distinguishing DLE and was
more common in patients with SCLE (David-Bajar et al., 1992).Table 1
Comparison of 4 EADV criteria between CLE subtypes (Beutner et al., 1991)
Criteria Localized
DLE
Generalized
DLE
SCLE
Malar rash 27% 20% 94%
Discoid rash 100% 100% 43%
Alopecia (nonscarring diffuse) 0% 0%⁎ 49%
Psoriasiform and/or annular polycyclic
type lesions
16%⁎ 32% 100%
⁎ p b 0.0001; no statistically signiﬁcant difference between SCLE and other CLE
subtypes.Beutner et al. (1991) presented their results utilizing new criteria
developed by the European Academy of Dermatology and Venerology
to classify CLE relative to other photodistributed skin eruptions. The
new criteria comprised the 11 American College of Rheumatology
criteria plus an additional 13 new criteria. Four out of these 24 new
European Academy of Dermatology and Venerology criteria were
dermatologic in nature: malar rash, discoid lesions, nonscarring diffuse
alopecia, and psoriasiform and/or annular polycyclic type lesions.
Alopecia, deﬁned as nonscarring and diffuse, was more common in
patientswith SCLE than localizedDLE (Table1). Asmentionedprevious-
ly, 43% of patients with SCLE were classiﬁed with discoid rash, whereas
32% of generalized DLE patients were classiﬁed with psoriasiform and/
or polycyclic type lesions, highlighting the uncertainty that exists
when making a clinical diagnosis of CLE subtype.
Walling and Sontheimer (2009) described active DLE lesions as
being indurated. David-Bajar et al. (1992) also investigated
whether induration could distinguish between DLE and SCLE le-
sions. These authors found that 100% of DLE lesions (n= 11) had
induration compared with 0% of SCLE lesions (n = 7). They con-
cluded that induration is useful in differentiating early active
DLE lesions from SCLE.
However, unpublished data from a study one of our authors
(V.P.W.) is currently undertaking calls into question the utility of in-
duration as a distinguishing feature of DLE lesions. In this study, two
raters, one dermatologist (V.P.W.) and one pre- or postdoctoral auto-
immune skin disease research fellow, independently assessed CLE- Peripheral scale with central
hypopigmentation
surfaces (face, ears, scalp)
- Adherent scale extending hair
follicles leading to follicular
plugging
- Characteristic histologic alterations
(ortho-hyperkeratosis of the epidermis,
dilated follicular oriﬁces ﬁlled with
compact keratin, vacuolar degeneration
of the basal keratinocytes, perivascular
and perifollicular mononuclear cell
inﬁltrate of the dermis)
- Center of lesion hypopigmented
and atrophic leading to a
depressed scar
- Evolution of lesions with atrophy, scar
formation, and pigmentary changes
- More than half of patients will
develop destructive scarring
- Positive lupus band test on lesional sun
exposed skin
- Histopathology qualitatively
similar in each CLE subtype and
not useful in determining clinical
skin type
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include 20 lesions evaluated in eight subjects (seven DLE, one
SCLE). Of the 20 lesions, 18 were DLE and twowere SCLE, with a clin-
ical diagnosis givenby the dermatologist (V.P.W.). Of the lesions eval-
uated, 17% to 22% of DLE lesions had induration, comparedwith 0% of
SCLE lesions, and all induration was classiﬁed as mild. Additionally,
when raters were asked to report their level of conﬁdence in
assessing induration, both raters reported moderate levels of conﬁ-
dence with average conﬁdence scores of 5.6 and 6.6 (out of 10) for
rater 1 and rater 2, respectively.
The fact that neither rater had a high level of conﬁdence in
assessing induration calls into question the feasibility of determining
the presence or absence of this feature. If it is difﬁcult for dermatolo-
gists to determine whether a lesion has induration, it might be chal-
lenging for nondermatologists as well. Additionally, it may be
difﬁcult to determinewhether hardening of a lesion is a result of epi-
dermal hypertrophy or dermal involvement. Therefore, including in-
duration as criterion for DLE may be problematic.
Clinical characteristics of DLE damage
BothWalling and Sontheimer (2009) and Fabbri et al. (2003) de-
scribe progression of an active DLE lesion to dyspigmented, atrophic
scar. David-Bajar et al. (1992) also found scarring to be helpful in
distinguishing DLE lesions. One study demonstrated a different pat-
tern in the Cutaneous Lupus Erythematosus Disease Area and
Severity Index activity and damage scores of patients with SCLE and
DLE (Bonilla-Martinez et al., 2008). In patients with DLE, damage
scores can continue to risewhile activity scores decrease. This pattern
of activity and damage reﬂects the characteristic course of the lesions,
which can have coexisting features of activity and damage simulta-
neously. In contrast, damage in SCLE tends to be minimal and,
when present, roughly follows the trajectory of activity. Although
features of damage may not be useful in distinguishing early DLE
lesions, they would be helpful in classifying patients with DLE for
clinical trials, which can include patients with a long-standing history
of disease.
Histopathologic characteristics of DLE
Walling and Sontheimer (2009) and Fabbri et al. (2003) treat his-
topathology differently in their criteria for the diagnosis of DLE.
Walling and Sontheimer (2009) comment that histopathology is sim-
ilar among CLE subtypes and is overall not useful in differentiating
one subtype from another. Fabbri et al. (2003) list a number of fea-
tures that can be found on histology in cases of DLE, but also note
that DLE shares similar histologic features with SCLE.
There have been three major studies to determine whether DLE
can be distinguished from SCLE histologically and to identify the fea-
tures that favor diagnosis of a speciﬁc CLE subtype (Table 4). Bangert
et al. (1984) identiﬁed ﬁve histologic features—hyperkeratosis, base-
ment membrane thickening, follicular damage, leukocytic inﬁltra-
tion, and involvement of the deep dermis—to favor the diagnosis of
DLE, a ﬁnding not duplicated by a second study (Jerden et al.,
1990). Two of the ﬁve features proposed by Bangert et al. (1984), de-
gree of dermal inﬂammation and hyperkeratosis, favored the correct
diagnosis of CLE subtype in 84% of cases in a third study (David-Bajar
et al., 1992). They did not report the sensitivity or speciﬁcity of using
these criteria for DLE histopathologic diagnosis.
Existing research suggests that histopathologymay behelpful, but
not deﬁnitive, in the diagnosis of CLE subtype. Two of these studies
showed that CLE subtype could be predicted in a majority of cases
(David-Bajar et al., 1992; Bangert et al., 1984); however, the study
with the largest cohort of patients demonstrated that CLE subtype
could not be predicted on the basis of histopathologic featuresalone (Table 4) (Jerden et al., 1990). It is reasonable to conclude
that although histologymay be helpful in some cases, there is a strong
need for clinicopathologic correlation in the diagnosis of DLE. There-
fore, histopathologic features have a limited role in the classiﬁcation
criteria for this disease.
Immunopathologic characteristics of DLE
Fabbri et al. (2003) state that a positive direct immunoﬂuores-
cence (DIF) on lesional sun-exposed skin suggests DLE. Positive DIF
on lesional skin was among the 13 additional criteria investigated
by Beutner et al. (1991), and the DIF was positive in 95% of localized
DLE cases compared with 40% of SCLE and 37% of generalized DLE. In
this study, a testwaspositivewith thepresenceof coarse granular de-
posits of immunoglobulin (Ig) G, IgM, and/or IgA at the dermal–
epidermal junction (DEJ).
The presence of a positive DIF in 20% of normal sun-exposed skin
of nonlupus patients might explain the increased incidence of posi-
tive DIF in localized DLE lesions, which are frequently located in
sun-exposed areas (Fabré et al., 1991). A follow-up study was not
able to reproduce these ﬁndings (Leibold et al., 1994). Although it is
possible that a continuous granular band of IgG at the DEJ in lesional
skin could be speciﬁc for CLE, further studies would need to be per-
formed to determine whether this ﬁnding is indicative of DLE
speciﬁcally.
Researchers have also looked at the differences in class of
immunoreactant deposited along the DEJ in different subtypes of
CLE (Table 4). One study found a higher percentage of SCLE speci-
mens containing IgG than DLE specimens (Table 4). Elsewhere, IgG
has been reported to be the most commonly deposited
immunoreactant in DLE (Kulthanan et al., 1996; Weigand, 1989). A
more recent study looked at immunoreactant deposition in a larger
cohort of 63 CLE patients (50 DLE, 13 SCLE) and found no clear differ-
ence in types of immunoglobulin present between CLE subtypes
(Table 5) (Kontos et al., 2005). The only signiﬁcant pattern observed
in this study was the presence of a staining combination pair IgG/
ﬁbrinogen in DLE (Kontos et al., 2005).
However, therewas a difference in the pattern of immunoﬂuores-
cence in DLE and SCLE samples (David-Bajar et al., 1992). DLE speci-
mens had particulate staining of both IgG and IgM that was localized
to the DEJ. However, SCLE specimens exhibited a particulate staining
of IgG through the epidermis exclusively and an extensive particulate
staining pattern of IgM that extended through the lower epidermis
and upper dermis (David-Bajar et al., 1992). The pattern of immuno-
ﬂuorescence with IgM has also been observed with IgG in SCLE spec-
imens (Nieboer et al., 1988). However, other studies have found this
pattern to be infrequent and not exclusively expressed in SCLE spec-
imens (Lipsker et al., 1998).
Immunoﬂuorescence may be useful when trying to differentiate
DLE from other mimickers, such as lichen planus or lichen
planopilaris. One study found a speciﬁcity of 0.97 in the diagnosis of
DLE by immunoﬂuorescence alone using presence of a sharply de-
marcated band of IgG or IgM at the basement membrane zone
(BMZ) in combination with C3c and C3d granular or homogenous
band-like pattern as a positive test result (Nieboer, 1987). This spec-
iﬁcity of diagnosis by IF was higher than histopathology alone (0.84)
and the combined methods (0.87), but this difference was not statis-
tically signiﬁcant (Nieboer, 1987). This suggests that IF might be
helpful in differentiating DLE from other lichenoid processes.
A more recent study into the immunopathology of lupus has the
potential to help with the classiﬁcation of CLE subtype in the future.
Active and chronic DLE lesions have a greater expression of
laminin-332 than SCLE lesions or normal skin (Al-Refu andGoodﬁeld,
2010). In addition, BMZ components laminin-332 and types IV and
VII collagen extend into the papillary dermis in active DLE lesions
Table 4
Ability to differentiate CLE subtype by histological examination (Bangert et al., 1984; Jerden et al., 1990; David-Bajar et al., 1992)
Study No. of specimens Study ﬁndings Accuracy
DLE
Accuracy for CLE
subtype
Bangert et al.
(1984)
38 (12 SCLE, 26
DLE)
Hyperkeratosis, basement membrane thickening, follicular damage, leukocytic inﬁltration,
involvement of the deep dermis favored diagnosis of DLE
77% 82%
Jerden et al.
(1990)
77 (36 SCLE, 40
DLE, 1 ACLE)
Could not successfully differentiate CLE subtype based on histologic features 55% 49%
David-Bajar
et al. (1992)
17 (7 SCLE, 10
DLE)
Increased intensity of dermal inﬂammation and degree of hyperkeratosis correlated with clinical
diagnosis of DLE
Not
reported
84%
ACLE = acute cutaneous lupus erythematosus; CLE = cutaneous lupus erythematosus; DLE = discoid lupus erythematosus; SCLE = subacute cutaneous lupus erythematosus.
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these components are restricted to the BMZ (Al-Refu and Goodﬁeld,
2010). Pattern of expression of laminin-332 and types IV and VII col-
lagen would be particularly helpful in differentiating early DLE le-
sions without scarring from those of SCLE.
Overall, DIF has a limited role in the diagnosis of CLE subtype. The
type of immunoreactant deposited atDEJ inDIF samples is not helpful
in differentiating one subtype from another if these observations are
validated. The differences in staining pattern found by David-Bajar
et al. (1992) are interesting but found in a small sample. Differences
in expression and pattern of BMZ components may be useful in the
diagnosis of DLE, although the process is costly and not readily avail-
able and validated in all practices.
Serological characteristics of DLE
Neither Walling and Sontheimer (2009) nor Fabbri et al. (2003)
comment on the role of serology in the diagnosis of DLE. Ro/SSA pos-
itivity is a feature that has been associated with SCLE and thought to
be unusual in DLE,making absence of Ro/SSA a potentially good crite-
rion for the classiﬁcation of DLE.
One study done looked the results of serologic analysis of 32 pa-
tients (17 SCLE, 15 DLE) using different assays and isoforms of Ro/
SSA antibody and found that all SCLE patients were positive for Ro/
SSA-60kd on immunodiffusion compared with 7% (1/15) of DLE pa-
tients (Lee et al., 1994). Only 71% (12/17) of SCLE patients were pos-
itive for Ro/SSA-60kd on immunoblotting, which the authors
attributed to loss of epitope binding site after protein denaturing
(Lee et al., 1994). High titers of anti-SSA antibody on enzyme-linked
immunosorbent assay were found in 100% of SCLE patients in the
study. High titers of anti-SSA antibody were only found in one DLE
patient, and low titers of anti-SSA antibody were found in one-third
of DLE patients (Lee et al., 1994). Enzyme-linked immunosorbent
assay is a useful method of serologic sampling because titer levels
are important in distinguishing DLE from SCLE.
Evaluating patients for anti-Ro/SSA antibodies could be useful in
making a diagnosis of CLE subtype when titer level of antibodies
can be determined. High titer Ro/SSA antibodies suggest SCLE,
whereas the absence of high titer SSA antibodies suggests another
subtype of CLE. High titer Ro/SSA does not exclude DLE because one
DLE patient in the prior study did have high titer Ro/SSA antibody.
However, absence of high titer Ro/SSA antibody might serve as a
good metric to steer away from a diagnosis of SCLE.Table 5
Differences in immunoreactant class deposition in CLE subtypes (David-Bajar et al., 1992; K
Study CLE subtype IgM
David-Bajar et al. (1992) DLE (n = 10) 73%
SCLE (n = 7) 100%
Kontos et al. (2005) DLE (n = 50) 78%
SCLE (n = 13) 62%
DLE = discoid lupus erythematosus; SCLE = subacute cutaneous lupus erythematosus.Conclusions and future directions
Prior research has proven localization of lesions to the head and
neck and characteristic features of damage such as dyspigmentation
and scarring to be helpful clinically in distinguishing DLE lesions
from those of SCLE. Histopathologic and immunopathologic evalua-
tion have been shown to be an unreliable means of determining
CLE subtype. Clinicopathologic correlation remains necessary to
make a diagnosis. Lack of high titer Ro/SSA antibodies ismore sugges-
tive of DLE, whereas presence of high titer Ro/SSA antibodies is more
suggestive of SCLE.
Early active lesions of DLE are the most difﬁcult to distinguish
from other subtypes of CLE. Induration was discussed as a potential
distinguishing feature of DLE lesions; however, it is variable and dif-
ﬁcult to assess. There is a need for further research on methods to
characterize CLE subtype to enable development of reliable ways to
differentiate DLE from other subtypes. This is important to manage
patient expectations, predict prognosis, and classify patients for clin-
ical trials. However, it is also important to keep classiﬁcation criteria
separate from diagnostic criteria and their respective potential utili-
ties. We have focused on classiﬁcation and research to begin this ef-
fort. Since there is a strong need for better treatments for CLE, it is
important that we are able to classify our patients in order to launch
clinical trials with novel medications. Classiﬁcation of DLE is part of a
larger process that can serve to advance treatment of and knowledge
about this disease so that we can take better care of our patients in
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